Vimarsana.com

Latest Breaking News On - Nasdaq vxrt - Page 1 : vimarsana.com

Vaxart (NASDAQ:VXRT) vs. Alvotech (NYSE:ALVO) Head to Head Contrast

Vaxart (NASDAQ:VXRT – Get Free Report) and Alvotech (NYSE:ALVO – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership. Risk and Volatility Vaxart has a beta of 0.43, meaning […]

South-san-francisco
California
United-states
Iceland
Reykjavik
C10
Altesa-biosciences-inc
Vaxart-inc
Get-free-report
Given-vaxart
Altesa-biosciences

Vaxart (NASDAQ:VXRT) Stock Price Passes Below 200-Day Moving Average of $0.82

Vaxart, Inc. (NASDAQ:VXRT – Get Free Report) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.82 and traded as low as $0.70. Vaxart shares last traded at $0.74, with a volume of 512,229 shares changing hands. Analysts Set New […]

Charles-schwab-investment-management-inc
Wealth-management
Vaxart-inc
Nasdaq
Cantor-fitzgerald
Jpmorgan-chase-co
Get-free-report
Stock-down
Sigma-advisers
Charles-schwab-investment-management
Schwab-investment-management

Vaxart (NASDAQ:VXRT) Share Price Crosses Below 200-Day Moving Average of $0.84

Vaxart, Inc. (NASDAQ:VXRT – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.84 and traded as low as $0.69. Vaxart shares last traded at $0.70, with a volume of 466,763 shares trading hands. Analysts Set New Price Targets Separately, […]

Montreal
Quebec
Canada
Vaxart-inc
Vaxart-company-profile
Cantor-fitzgerald
Schonfeld-strategic-advisors
Nasdaq
Get-free-report
Sigma-advisers
Montreal-can

Vaxart (NASDAQ:VXRT) Given "Overweight" Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Vaxart (NASDAQ:VXRT – Free Report) in a research report released on Thursday, Benzinga reports. The firm currently has a $4.00 target price on the biotechnology company’s stock. Vaxart Price Performance Shares of NASDAQ VXRT opened at $0.78 on Thursday. The stock has a market capitalization of […]

Metlife-investment-management
Vanguard-group-inc
Vaxart-inc
Charles-schwab-investment-management-inc
Vaxart-company-profile
Jpmorgan-chase-co
Cantor-fitzgerald
Free-report
Get-free-report
Life-investment-management
Charles-schwab-investment-management

vimarsana © 2020. All Rights Reserved.